Optimism for J & J, Kenvue The news : Investors should buy shares of Johnson & Johnson for its "world-leading medical technology and pharmaceutical franchises," Citigroup analysts wrote in a research note Tuesday.
The firm, after a period of restriction, resumed its J & J coverage with a buy rating and $185-per-share price target.
Jim said Tuesday he could see J & J jumping to around $170 per share, if plaintiffs were to approve the company's proposed settlement .
J & J has long rejected plaintiffs' claims that its baby powder and other talc products caused cancer.
In any case, we like Kevnue as a standalone company and will keep a close eye on its performance as we await more information from J & J management on finalizing the divestiture.
Organizations:
& $